Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SIL 204

Next Previous
Drug Profile

SIL 204

Alternative Names: KRASG12D-LODER; siG12D-LODER; SIL-204

Latest Information Update: 10 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Silenseed
  • Developer Silexion Therapeutics
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action KRAS protein expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Pancreatic cancer
  • Preclinical Colorectal cancer; Lung cancer

Most Recent Events

  • 04 Aug 2026 Pharmacodynamics data from a preclinical trial in Pancreatic cancer and non-small cell lung cancer released by Silexion Therapeutics
  • 29 Jul 2026 Phase-II/III clinical trials in Pancreatic cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable, Combination therapy) in Israel (Intratumoural)
  • 29 Jul 2026 Silexion Therapeutics plans a phase II/III trial for Pancreatic cancer (Late-stage disease, Adjunctive therapy) in Israel in July 2026 (CTIS2025-525157-39-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top